Influence of atrial fibrillation subtypes on anticoagulant therapy in a high-risk older population: the FAI project

Abstract

Background and aim Benefits of oral anticoagulants (OAC) in atrial fibrillation (AF) patients with moderate-to-high risk of stroke are independent of AF pattern. We evaluated whether AF clinical subtype influenced OAC use in a representative sample of the Italian older population. Methods A cross-sectional examination of all subjects aged 65 + years from three general practices in northern, central, and southern Italy started in 2016. A double-screening procedure was followed by clinical and ECG confirmation. Patients were categorized as having paroxysmal, persistent, or permanent AF. OAC use was evaluated in confirmed AF patients. Results The sample included 6016 subjects. Excluding 235 non-eligible, participation was 78.3%, which left 4528 participants (mean age 74.5 ± 6.8 years, 47.2% men). Overall, 319 AF cases were identified: 43.0% had paroxysmal, 21.3% persistent, and 35.7% permanent AF. Frequency of OAC therapy was 91.2% in permanent, 85.3% in persistent, and only 43.0% in paroxysmal AF (P < 0.001). In multivariate analysis, controlled for baseline variables and risk scales, persistent and permanent AF were associated with a significant increase in the likelihood of receiving OAC compared with paroxysmal AF (P < 0.001). This was confirmed for permanent AF also in multivariate analyses considering separately vitamin K antagonists or direct-acting oral anticoagulants (OR, 4.37, 95% CI, 2.43–7.85; and 1.92, 95% CI, 1.07–3.42, respectively) and for persistent AF and direct-acting oral anticoagulants (OR, 4.33, 95% CI, 2.30–8.15). Conclusions In a population-based survey, AF pattern was an independent predictor of OAC treatment. Paroxysmal AF is still perceived as carrying a lower risk of vascular events.

Atrial conduction velocity mapping: clinical tools, algorithms and approaches for understanding the arrhythmogenic substrate

“…Atrial arrhythmias, including atrial fibrillation (AF), are a major global health problem; AF was estimated to affect 7.6 million people over 65 in the EU in 2016 [1]. To improve therapeutic strategies, which include anti-arrhythmic drug therapy and radiofrequency catheter ablation therapy, an improved understanding is needed of the factors underlying the arrhythmia of each individual patient.…”